Inducible tyrosine kinase inhibitors: A review of the patent literature (2010-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 9, 2014, Pages 979-991

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

Asthma; Bruton's tyrosine kinase inhibitor; Inducible tyrosine kinase inhibitor; Rheumatoid arthritis; Tec inhibitor; Thymus cell

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; IBRUTINIB; INDUCIBLE TYROSINE KINASE INHIBITOR; JANUS KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ASTHMA; CRYSTAL STRUCTURE; DRUG INDUSTRY; DRUG USE; HUMAN; NATURAL KILLER T CELL; NONHUMAN; PATENT; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; TOBACCO; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DRUG DESIGN; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; AUTOIMMUNE DISEASES; DRUG DESIGN; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84906216493     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.936381     Document Type: Review

References (66)

1. Hendriks RW, Yuvaraj S, Kil LP. Targeting bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014;14(4):219-32
2. Whang JA, Chang BY. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today 2014. [Epub ahead of print]
3. Schaeffer EM, Debnath J, Yap G. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 1999;284:638-41
4. Gomez-Rodriguez J, Kraus ZJ, Schwartzberg PL. Tec family kinases Itk and Rlk/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J 2011;278(12):1980-9
5. von Bonin A, Rausch A, Mengel A, et al. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol 2011;20(1):41-7
6. Vargas L, Hamasy A, Nore BF, Smith CI. Inhibitors of BTK and Itk: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol 2013;78(2):130-9
7. Lo HY. Itk inhibitors, a Patent Review. Exp Opin Ther Patents 2010;4):459-69
8. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase Itk. J Immunol 2003;170(10):5056-63
9. August A, Ragin MJ. Regulation of T-cell responses and disease by tec kinase Itk. Int Rev Immunol 2012;31(2):155-65
10. Qi Q, Kannan AK, August A. Tec family kinases: itk signaling and the development of NKT alpha beta and gamma delta T cells. FEBS J 2011;278(12):1970-9
11. Kannan Y, Wilson MS. TEC and MAPK kinase signalling pathways in t helper (th) cell development, th2 differentiation and allergic asthma. J Clin Cell Immunol 2012;S12:1-15
12. Gomez-Rodriguez J, Wohlfert EA, Handon R, et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med 2014;211(3):529-43
13. Prince AL, Yin CC, Enos ME, et al. The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development. Immunol Rev 2009;228(1):115-31
14. Horwood NJ, Urbaniak AM, Danks L. Tec family kinases in inflammation and disease. Int Rev Immunol 2012;31(2):87-103
15. Kim KH, Maderna A, Schnute ME, et al. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett 2011;21(21):6258-63
16. Brown K, Long JM, Vial SC, et al. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J Biol Chem 2004;279(18):18727-32
17. Vertex Pharmaceuticals, Inc. 3,5-Disubstituted Pyrid-2-Ones useful as inhibitors of tec family of non-receptor tyrosine kinases. WO2007027594; 2007
18. Storck P, Charrier J-D, Miller A, et al. Role for hydration in rationalizing the potency and selectivity of novel Itk inhibitors. 245th ACS Meeting; 10 April 2013, MEDI Available from http://abstracts.acs.org//chem/ 245nm/program/view.php?pub-num=54&par=MEDI
19. Charrier J-D, Miller A, Hay DP, et al. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible t-cell kinase (itk) inhibitors. J Med Chem 2011;54(7):2341-50
20. Japan Tobacco, Inc. Indole compound and pharmaceutical use thereof. WO2011065402; 2011
21. Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof. WO2013024427; 2013
22. Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors. WO2013153539; 2013
23. Glenmark Pharmaceuticals S.A. Heterocyclic amides as itk inhibitors. WO2014024119; 2014
24. Glenmark Pharmaceuticals S.A. Thienopyrrole derivatives As Itk inhibitors. WO2014041518; 2014
25. F Hoffmann-La Roche AG. Indazole compounds, compositions and methods of use. WO2013024011; 2013
26. MacKinnon CH, Lau K, Burch JD, et al. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (Itk). Bioorg Med Chem Lett 2013;23(23):6331-5
27. Pastor RM, Burch JD, Magnuson S, et al. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (Itk) inhibitors. Bioorg Med Chem Lett 2014;24(11):2448-52
28. F.Hoffmann-La Roche AG, Genentech, Inc. Pyrazole carboxamide compounds, compositions and methods of use. WO2014023258; 2014
29. Glaxo Group Ltd. pyrimidine derivatives used as Itk inhibitors. WO2010106016; 2010
30. Glaxo Group Ltd. Derivatives of 2-[2-(benzo-or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases. WO 2011110575; 2011
31. Glaxo Group Ltd. Novel compounds. WO2012035055; 2012
32. Harling JD, Deakin AM, Campos S, et al. Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket. J Biol Chem 2013;288(39):28195-206
33. Alder CM, Ambler M, Campbell AJ, et al. Identification of a novel and selective series of itk inhibitors via a template-hopping strategy. ACS med. Chem Lett 2013;4(10):948-52
34. Campos S. Development of irreversible Itk inhibitors as a potential new treatment for severe asthma. 25th symposium on Medicinal Chemistry in Eastern England, Hatfield; 24 April 2013
35. Locus pharmaceuticals aminopyrazine compounds. WO2012121939; 2012
36. Amgen, inc. Bis-aryl amide derivatives useful for the treatment of cancer. WO2008086014; 2008
37. Zapf CW, Gerstenberger BS, Xing L, et al. Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay. J Med Chem 2012;55(22):10047-63
38. Han S, Czerwinski RM, Caspers NL, et al. Selectively targeting an inactive conformation of IL-2-induced T cell kinase by allosteric inhibitors. Biochem J 2014;460(2):211-22
39. Zapf CW. Itk Inhibitors for the Treatment of Asthma-Approaches to Overcome the Biochemical Efficiency Hurdle, GTC Bio. 2nd Allergy and Respiratory Drug Discovery Conference; 31 January 2013
40. Evans EK, Tester R, Aslanian S, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 2013;346(2):219-28
41. Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof. WO2009158571; 2009
42. Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof. WO-2010123870; 2010
43. Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof. WO2011090760; 2011
44. Biogen Idec, Inc., Sunesis Pharmaceuticals, Inc. Heteroaryl Btk inhibitors. WO2011029043; 2011
45. Biogen Idec, Inc., Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors. WO2011029046; 2011
46. Biogen Idec, Inc., Sunesis Pharmaceuticals, Inc. Heterocyclic tyrosine kinase inhibitors. WO2012058645; 2012
47. University of California. Imidazoquinoxalinones and anti-tumor treatment. WO2011017219; 2011
48. Bristol-Myers Squibb Co. Carboline carboxamide compounds useful as kinase inhibitors. WO2011159857; 2011
49. Das J, Furch JA, Liu C, et al. Discovery and SAR of 2-amino-5-(thioaryl) thiazoles as potent and selective Itk inhibitors. Bioorg Med Chem Lett 2006;16:3706-12
50. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013;6:59
51. Hanmi Holdings Co Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity. WO2011162515; 2011
52. Hanmi Pharmaceutical Co Ltd. Novel imidazopyridine derivatives as a tyrosine kinase inhibitor. WO2013100631; 2013
53. Hanmi Pharmaceutical Co Ltd. Triazolopyridine derivatives as a tyrosine kinase inhibitor. WO2013118986; 2013
54. Cellzome Ltd. Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors. WO2013041605; 2013
55. Korea Institute Of Science And Technology. 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors. WO2011049332; 2011
56. Hill RJ, Bisconte A, Bradshaw JM, et al. Discovery of a highly potent, selective, reversible covalent inhibitor of JAK3. Arthritis Rheum 2012;64(Suppl 10):2326
57. Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors. WO2010054107; 2010
58. Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors. WO2010065898; 2010
59. Principia Biopharma, Inc. Azaindole derivatives as tyrosine kinase inhibitors. WO2012158785
60. Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors. WO2012158795; 2012
61. Principia Biopharma, Inc. Tyrosine kinase inhibitors. WO2012158810; 2012
62. Dana-Farber Cancer Institute. Inc-Egfr inhibitors and methods of treating disorders. WO2010129053; 2011
63. Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith. WO2011140338; 2011
64. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462(7276):1070-4
65. Zhou W, Ercan D, Jänne PA, Gray NS. Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 2011;21(2):638-43
66. Joseph RJ, Andreotti AH. Controlling the activity of the Tec kinase Itk by mutation of the. phenylalanine gatekeeper residue. Biochemistry 2011;50(2):221-9